De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Orchid Pharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Orchid Pharma heeft een totaal eigen vermogen van ₹11.7B en een totale schuld van ₹1.4B, wat de schuld-eigenvermogensverhouding op 11.6% brengt. De totale activa en totale passiva bedragen respectievelijk ₹15.5B en ₹3.8B. De EBIT Orchid Pharma is ₹872.4M waardoor de rentedekking -42.8 is. Het heeft contanten en kortetermijnbeleggingen van ₹36.2M.

Belangrijke informatie

11.6%

Verhouding schuld/eigen vermogen

₹1.35b

Schuld

Rente dekkingsratio	-42.8x
Contant	₹36.16m
Aandelen	₹11.69b
Totaal verplichtingen	₹3.84b
Totaal activa	₹15.54b

Recente financiële gezondheidsupdates

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Feb 06

Recent updates

Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%

Jul 29

We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Jun 12

Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

May 08

Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Feb 28

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Feb 06

Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Dec 18

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹7.9B ) ORCHPHARMA } overtreffen de korte termijn passiva ( ₹2.6B ).

Langlopende schulden: De kortetermijnactiva ORCHPHARMA ( ₹7.9B ) overtreffen de langetermijnschulden ( ₹1.2B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 11.3% ) ORCHPHARMA wordt als voldoende beschouwd.

Schuld verminderen: ORCHPHARMA had 5 jaar geleden een negatief eigen vermogen, maar is nu positief en is dus verbeterd.

Schuldendekking: De schuld van ORCHPHARMA wordt goed gedekt door de operationele kasstroom ( 93.2% ).

Rentedekking: ORCHPHARMA verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Orchid Pharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Recent updates

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued

Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%

Orchid Pharma Limited to Report Q4, 2025 Results on May 30, 2025

Orchid Pharma Limited, Annual General Meeting, Aug 21, 2024

Orchid Pharma Limited, Annual General Meeting, Aug 21, 2024

Investor sentiment improves as stock rises 24%

We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Orchid Pharma Receives DCGI Approval for Its First Invented and Made-In-India Antibiotic Drug Combination of Cefepime and Enmetazobactam

Now 20% undervalued after recent price drop

Orchid Pharma Limited Appoints Shubha Singh as Additional Director

Orchid Pharma Limited to Report Q4, 2024 Results on May 23, 2024

Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director

Now 25% overvalued after recent price rise

Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Investor sentiment improves as stock rises 27%

Now 29% overvalued after recent price rise

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Orchid Pharma Limited to Report Q3, 2024 Results on Feb 08, 2024

European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep'

Investor sentiment improves as stock rises 20%

Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer

Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer

Second quarter 2024 earnings released: EPS: ₹4.30 (vs ₹1.32 loss in 2Q 2023)

Orchid Pharma Limited to Report Q2, 2024 Results on Nov 04, 2023

Orchid Pharma Limited Approves the Appointment of Mr. Arjun Dhanuka as Additional Director (In Capacity of Non-Executive & Non-Independent)

Orchid Pharma Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: EPS: ₹13.01 (vs ₹14.80 loss in FY 2022)

Investor sentiment improves as stock rises 16%

Orchid Pharma Limited, Annual General Meeting, Aug 09, 2023

Insufficient new directors

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 15%

Full year 2023 earnings released: EPS: ₹13.01 (vs ₹14.80 loss in FY 2022)

Third quarter 2023 earnings released: EPS: ₹1.86 (vs ₹2.59 loss in 3Q 2022)

Orchid Pharma Limited Announces Demise of Arun Kumar Dhanuka, Non-Executive & Non-Independent Director

Second quarter 2023 earnings released

High number of new and inexperienced directors

Orchid Pharma Limited Announces Appointment of Marina Peter as Company Secretary and Compliance Officer

Now 21% undervalued

First quarter 2023 earnings released: ₹3.68 loss per share (vs ₹6.93 loss in 1Q 2022)

Orchid Pharma Limited to Report Q1, 2023 Results on Aug 10, 2022

Orchid Pharma Limited Announces Resignation of Nikita as Company Secretary and Compliance Officer

Now 22% undervalued after recent price drop

Full year 2022 earnings released

Orchid Pharma Limited, Annual General Meeting, Jul 15, 2022

Now 23% undervalued

Orchid Pharma Limited to Report Q4, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

New 90-day high: ₹823

Third quarter 2021 earnings released: ₹10.96 loss per share (vs ₹959 loss in 3Q 2020)

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven